Inconsistent state regulations, staff training produce wide variations among states’ antipsychotic...
By
Kimberly Bonvissuto
Feb 28, 2023
Researchers are calling for a closer look at the use of antipsychotics among assisted living residents with dementia after a study found wide variations in prescribing patterns.
Lawmakers chide HHS for ‘eroding the pathway’ to Alzheimer’s treatments
By
Kimberly Bonvissuto
Mar 24, 2023
With personal stories of the effects that Alzheimer’s disease has had on them, lawmakers in a Senate Finance Committee hearing on Wednesday called for the federal government to speed up access to treatments....
CMS officially removes one-time restriction for Alzheimer’s PET scan coverage
By
Aaron Dorman
Oct 17, 2023
Seniors covered by Medicare will now have expanded access to Alzheimer’s diagnostic PET scans after the CMS removed one-time restrictions.
Care use, financial burden increase over time for elders with dementia
Oct 16, 2023
Increases were seen in care hours from family and unpaid helpers, use of in-home medical care, hospital stay and use of a nursing facility.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Brain imaging company teases tech that will analyze side effects of new dementia drugs
By
Aaron Dorman
Nov 28, 2023
AI-enabled brain imaging technology will be launched next year to evaluate the side effects of new Alzheimer’s and dementia drugs.
Bipartisan group of 23 state AGs joins call for unrestricted coverage of Alzheimer’s treatments
By
Kimberly Bonvissuto
May 03, 2023
A bipartisan group of attorneys general from 23 states have joined a growing chorus calling on Medicare to reverse a previous decision and provide unrestricted coverage of Food and Drug Administration-approved...
Industry advocates join coalition to support federal bill requiring use of Alzheimer’s detection tools
By
Kimberly Bonvissuto
Oct 04, 2023
A bipartisan bill requiring the use of cognitive impairment detection tools in the early detection of Alzheimer’s disease and related dementias has the support of the senior living industry.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.